Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. BET bromodomain inhibitors, which have shown efficacy in several models of cancer have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such...

Full description

Bibliographic Details
Main Authors: Shu, Shaokun, Lin, Charles Y., He, Housheng Hansen, Witwicki, Robert M., Tabassum, Doris P., Roberts, Justin M., Janiszewska, Michalina, Jin Huh, Sung, Liang, Yi, Ryan, Jeremy, Doherty, Ernest, Mohammed, Hisham, Guo, Hao, Stover, Daniel G., Ekram, Muhammad B., Peluffo, Guillermo, Brown, Jonathan, D’Santos, Clive, Krop, Ian E., Dillon, Deborah, McKeown, Michael, Ott, Christopher, Qi, Jun, Ni, Min, Rao, Prakash K., Duarte, Melissa, Wu, Shwu-Yuan, Chiang, Cheng-Ming, Anders, Lars, Young, Richard A., Winer, Eric P., Letai, Antony, Barry, William T., Carroll, Jason S., Long, Henry W., Brown, Myles, Liu, X. Shirley, Meyer, Clifford A., Polyak, Kornelia, Bradner, James
Other Authors: Broad Institute of MIT and Harvard
Format: Article
Language:en_US
Published: Nature Publishing Group 2017
Online Access:http://hdl.handle.net/1721.1/109131

Internet

http://hdl.handle.net/1721.1/109131

Similar Items